Literature DB >> 2902896

Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study.

J A Stamford1, Z L Kruk, J Millar.   

Abstract

1. Fast cyclic voltammetry at carbon fibre microelectrodes was used to study the effects of several dopamine antagonists upon stimulated dopamine release in the rat striatum and nucleus accumbens. 2. In both nuclei, stimulated dopamine release was increased by D2-receptor-selective and mixed D1/D2-receptor antagonists. The D1-selective antagonist SCH 23390 had no effect. 3. Striatal and limbic dopamine release were elevated by cis- but not trans-flupenthixol. 4. The 'atypical' neuroleptics (clozapine and thioridazine) did not cause a selective elevation of dopamine release in the limbic terminal region, whereas the non-antipsychotic drug metoclopramide increased dopamine release more in striatum than nucleus accumbens. 5. We conclude from this study that striatal and limbic dopamine release are under the control of a stereoselective dopamine D2-autoreceptor on the nerve terminal and that atypical neuroleptics do not show a limbic-selective effect at this receptor after acute administration.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902896      PMCID: PMC1854028          DOI: 10.1111/j.1476-5381.1988.tb11605.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine.

Authors:  J Gerlach; H Simmelsgaard
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

Review 2.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

3.  Chlorpromazine; new inhibiting agent for psychomotor excitement and manic states.

Authors:  H E LEHMANN; G E HANRAHAN
Journal:  AMA Arch Neurol Psychiatry       Date:  1954-02

4.  Assessment of the neuroleptic potential of some novel benzamide, butyrophenone, phenothiazine and indole derivatives.

Authors:  B Costall; W H Funderburk; C A Leonard; R J Naylor
Journal:  J Pharm Pharmacol       Date:  1978-12       Impact factor: 3.765

5.  Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system.

Authors:  G Bartholini
Journal:  J Pharm Pharmacol       Date:  1976-05       Impact factor: 3.765

6.  Substituted benzamides as cerebral dopamine antagonists in rodents.

Authors:  P N Elliott; P Jenner; G Huizing; C D Marsden; R Miller
Journal:  Neuropharmacology       Date:  1977-05       Impact factor: 5.250

7.  Dopamine-sensitive adenylate cyclase in mammalian brain: a possible site of action of antipsychotic drugs.

Authors:  Y C Clement-Cormier; J W Kebabian; G L Petzold; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1974-04       Impact factor: 11.205

8.  Clozapine in tardive dyskinesia.

Authors:  G M Simpson; J H Lee; R K Shrivastava
Journal:  Psychopharmacology (Berl)       Date:  1978-01-31       Impact factor: 4.530

9.  The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs?

Authors:  T J Crow; J F Deakin; A Longden
Journal:  Psychol Med       Date:  1977-05       Impact factor: 7.723

10.  Dystonic reactions to metoclopramide (maxolon).

Authors:  M Reid
Journal:  Ulster Med J       Date:  1977
View more
  8 in total

1.  Drosophila Dopamine2-like receptors function as autoreceptors.

Authors:  Trisha L Vickrey; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2011-12-21       Impact factor: 4.418

2.  Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging.

Authors:  Yin-Ching I Chen; Ji-Kyung Choi; Susan L Andersen; Bruce R Rosen; Bruce G Jenkins
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

Review 3.  Effects of chronic neuroleptic treatment on dopamine release: insights from studies using 3-methoxytyramine.

Authors:  M F Egan; S Chrapusta; F Karoum; B K Lipska; R J Wyatt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Differential effects of dopamine agonists upon stimulated limbic and striatal dopamine release: in vivo voltammetric data.

Authors:  J A Stamford; Z L Kruk; J Millar
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

5.  Chronic clozapine versus chronic haloperidol treatment: differential effects on electrically evoked dopamine efflux in the rat caudate putamen, but not in the nucleus accumbens.

Authors:  K J Feasey-Truger; C Alzheimer; G ten Bruggencate
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-12       Impact factor: 3.000

6.  Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.

Authors:  R Rivest; C A Marsden
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

7.  Differences in evoked dopamine efflux in rat caudate putamen, nucleus accumbens and tuberculum olfactorium in the absence of uptake inhibition: influence of autoreceptors.

Authors:  S J Trout; Z L Kruk
Journal:  Br J Pharmacol       Date:  1992-06       Impact factor: 8.739

8.  Transcription factor SP4 is a susceptibility gene for bipolar disorder.

Authors:  Xianjin Zhou; Wei Tang; Tiffany A Greenwood; Shengzhen Guo; Lin He; Mark A Geyer; John R Kelsoe
Journal:  PLoS One       Date:  2009-04-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.